Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Conditions

Subcategories:Axial SpondyloarthritisClinical Criteria/GuidelinesGout and Crystalline ArthritisMyositisOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPain SyndromesPediatric ConditionsPsoriatic ArthritisRheumatoid ArthritisSjögren’s DiseaseSoft Tissue PainSystemic Lupus ErythematosusSystemic SclerosisVasculitis

New Kits Address Pediatric-to-Adult-Care Transition

Kurt Ullman  |  October 5, 2016

The transition from pediatric to adult care can be a rocky one. For many rheumatology patients, any problems in the move can cause gaps in care. To address this issue, the American College of Rheumatology (ACR) joined the American College of Physicians’ (ACP) Pediatric to Adult Care Transitions Initiative. The Initiative is a project spearheaded…

Anti-TNFs in Early Puberty May Improve Growth in Pediatric IBD

Reuters Staff  |  October 4, 2016

NEW YORK (Reuters Health)—Anti-TNF drugs are more likely to improve growth in children with inflammatory bowel disease (IBD) if they’re given in the earlier stages of puberty, new findings show.¹ Children who achieve remission are also more likely to have satisfactory growth, the research team reported online on Sept. 21 in the Journal of Pediatric…

The Role of Benign Joint Hypermobility in Functional Pain Disorders

Lara C. Pullen, PhD  |  October 3, 2016

Physicians have been puzzled by the role of benign joint hypermobility syndrome in the development of gastrointestinal disorders and other autonomic symptoms and co-morbidities. However, new research found that benign joint hypermobility syndrome only minimally affects autonomic abnormalities…

Pregnancy Outcome in Early Rheumatic Disease

Arthritis & Rheumatology  |  September 28, 2016

Systemic autoimmune rheumatic diseases are associated with increased rates of adverse pregnancy outcomes, including spontaneous abortion, preeclampsia, fetal growth restriction (FGR) and prematurity. In this study population, preclinical rheumatic disorders were associated with an increased risk of FGR, preeclampsia and small-for-gestational-age infants. The impact of these findings and their utility in screening for fetal growth restriction/preeclampsia need to be confirmed in population studies…

Why Rheumatologists Should Care about Zika: How It’s Transmitted & Spreading in the U.S.

Lara C. Pullen, PhD  |  September 26, 2016

Rheumatologists are already familiar with one mosquito-borne virus, chikungunya, whose presentation mimics arthritis. Now, with its recent spread to Puerto Rico and the Southeastern U.S., Zika, another mosquito-borne virus, has become an international public health concern. Sexual transmission of the virus was recently confirmed, expanding the virus’s threat…

Is Arthroscopic Meniscal Surgery Effective?

Lara C. Pullen, PhD  |  September 19, 2016

A recent review examined the effectiveness of arthroscopic mensical surgery in treating meniscal injuries. Researchers determined that little evidence exists to support the use of arthroscopic meniscal surgery and more studies that directly compare it with nonoperative treatments are needed…

Novel Astrocytic Autoantibody Associated with Relapsing Meningoencephalomyelitis

Will Boggs, MD  |  September 18, 2016

NEW YORK (Reuters Health)—An autoantibody to glial fibrillary acidic protein (GFAP) is associated with relapsing autoimmune meningoencephalomyelitis that is responsive to immunotherapy, researchers report. “Autoimmune GFAP meningoencephalomyelitis is the second autoimmune neurological disease in which the target of the immune attack is recognized to be the astrocyte type of brain cell,” Dr. Vanda A. Lennon…

Abaloparatide Promising for Osteoporosis; NICE Draft Guidelines Include Secukinumab for Ankylosing Spondylitis

Michele B. Kaufman, PharmD, BCGP  |  September 14, 2016

In a clinical trial, subcutaneous abaloparatide has proved effective in treating postmenopausal women with osteoporosis. Also in the U.K., draft guidelines for treating ankylosing spondylitis will recommend the use of secukinumab…

Diagnostic Criteria, Classification Lacking for Vasculitis; New Research in Treatment for Systemic Sclerosis

Thomas R. Collins  |  September 12, 2016

LONDON—Despite the detailed terminology for describing vasculitis established by the Chapel Hill Consensus (CHC) in 2012, the field badly needs better classification and diagnostic criteria for the group of diseases, an expert said in a presentation at the Annual Congress of the European League Against Rheumatism (EULAR 2016). It’s a topic that is now being…

Research on Ixekizumab in Psoriatic Arthritis and More Presented at EULAR 2016

Thomas R. Collins  |  September 12, 2016

LONDON—Results from the extension phase of a Phase 3 trial for the IL-17A inhibitor ixekizumab in psoriatic arthritis (PsA) show that patients started on placebo, adalimumab and ixekizumab continued to show improvements in arthritis, dactylitis and ethesitis, said Philip Mease, MD, a rheumatologist at Swedish Medical Center University of Washington in Seattle.1 Dr. Mease presented the…

  • « Previous Page
  • 1
  • …
  • 211
  • 212
  • 213
  • 214
  • 215
  • …
  • 341
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences